Michael Kenston
Nessuna posizione attualmente
Profilo
Michael Kenston worked as a Director of Promotional Analytics at Abbott Laboratories, Vice President of Commercial Analysis at Reata Pharmaceuticals, Chief Commercial Officer at Melinta Subsidiary Corp., and VP of Business Development Search & Evaluation at Lundbeck, Inc. He holds an MBA from Indiana University and an undergraduate degree from Northern Illinois University.
Precedenti posizioni note di Michael Kenston
Società | Posizione | Fine |
---|---|---|
ABBOTT LABORATORIES | Corporate Officer/Principal | - |
REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Lundbeck, Inc.
Lundbeck, Inc. Pharmaceuticals: MajorHealth Technology Part of Lundbeck Foundation, Lundbeck, Inc. is a pharmaceutical company that produces pharmaceutical preparations. The company is based in Paramus, NJ. The company was founded by Jeffrey S. Aronin. | Corporate Officer/Principal | - |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Corporate Officer/Principal | - |
Formazione di Michael Kenston
Northern Illinois University | Undergraduate Degree |
Indiana University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ABBOTT LABORATORIES | Health Technology |
Aziende private | 3 |
---|---|
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Lundbeck, Inc.
Lundbeck, Inc. Pharmaceuticals: MajorHealth Technology Part of Lundbeck Foundation, Lundbeck, Inc. is a pharmaceutical company that produces pharmaceutical preparations. The company is based in Paramus, NJ. The company was founded by Jeffrey S. Aronin. | Health Technology |
- Borsa valori
- Insiders
- Michael Kenston